Small molecular inhibitors: Therapeutic strategies for pancreatic cancer.

Pancreatic cancer (PC), a disease with high heterogeneity and a dense stromal microenvironment, presents significant challenges and a bleak prognosis. Recent breakthroughs have illuminated the crucial interplay among RAS, epidermal growth factor receptor (EGFR), and hedgehog pathways in PC progression. Small molecular inhibitors have emerged as a potential solution with their advantages of oral administration and the ability to target intracellular and extracellular sites effectively. However, despite the US FDA approving over 100 small-molecule targeted antitumor drugs, challenges such as low response rates and drug resistance persist. This review delves into the possibility of using small molecules to treat persistent or spreading PC, highlighting the challenges and the urgent need for a diverse selection of inhibitors to develop more effective treatment strategies.

Epigenetics in hepatocellular carcinoma.

Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and has a high fatality rate. Genetic and epigenetic aberrations are commonly observed in HCC. The epigenetic processes include chromatin remodelling, histone alterations, DNA methylation, and noncoding RNA (ncRNA) expression and are connected with the progression and metastasis of HCC. Due to their potential reversibility, these epigenetic alterations are widely targeted for the development of biomarkers. In-depth understanding of the epigenetics of HCC is critical for developing rational clinical strategies that can provide a meaningful improvement in overall survival and prediction of therapeutic outcomes. In this article, we have summarised the epigenetic modifications involved in HCC progression and highlighted the potential biomarkers for diagnosis and drug development.

Epigenetics and therapeutic targets in gastrointestinal malignancies.

Gastrointestinal (GI) malignancies account for substantial mortality and morbidity worldwide. They are generally promoted by dysregulated signal transduction and epigenetic pathways, which are controlled by specific enzymes. Recent studies demonstrated that histone deacetylases (HDACs) together with DNA methyltransferases (DNMTs) have crucial roles in the signal transduction/epigenetic pathways in GI regulation. In this review, we discuss various enzyme targets and their functional mechanisms responsible for the regulatory processes of GI malignancies. We also discuss the epigenetic therapeutic targets that are mainly facilitated by DNMT and HDAC inhibitors, which have functional consequences and clinical outcomes for GI malignancies.

Horizons of nanotechnology applications in female specific cancers.

Female-specific cancers are the most common cancers in women worldwide. Early detection methods remain unavailable for most of these cancers, signifying that most of them are diagnosed at later stages. Furthermore, current treatment options for most female-specific cancers are surgery, radiation and chemotherapy. Although important milestones in molecularly targeted approaches have been achieved lately, current therapeutic strategies for female-specific cancers remain limited, ineffective and plagued by the emergence of chemoresistance, which aggravates prognosis. Recently, the application of nanotechnology to the medical field has allowed the development of novel nano-based approaches for the management and treatment of cancers, including female-specific cancers. These approaches promise to improve patient survival rates by reducing side effects, enabling selective delivery of drugs to tumor tissues and enhancing the uptake of therapeutic compounds, thus increasing anti-tumor activity. In this review, we focus on the application of nano-based technologies to the design of novel and innovative diagnostic and therapeutic strategies in the context of female-specific cancers, highlighting their potential uses and limitations.

Small-Molecule-Targeted Therapies for Gastrointestinal Cancer: Successes and Failures.

The genomic era witnessed the deciphering of molecular mechanisms underlying human gastric cancer (GC) that paved the way to specifically target key molecules or proteins involved in disease progression. A multifactorial disease, GC has a host of other factors that influence its initiation and progression such as age, gender, severe exposure to several environmental pressures, and inadequate diet. These aspects lead to changes at the molecular level that reflect at the protein level, thereby contributing to cancer. Targeting such specific proteins, widely referred to as targeted therapy (TT), is actively sought because it promises treatment precision. Several clinical trials are underway with candidate drugs and in combination with other lines of treatment such as chemotherapy and radiation therapy, for which results are varied. This review summarizes strategies that are involved in GC treatment, delving deeply into TT approaches (based on small molecules) that have already reached the clinic or are currently in clinical trials.

Circulating Biomarkers for the Early Diagnosis of Gastrointestinal Cancers.

Gastrointestinal (GI) cancer is a particularly sobering disease because it carries a high mortality rate. The characteristic tendency of GI cancers to reveal symptoms only in the malignant phase is the major contributing factor to its poor patient outcomes. Hence, it is critical to actively work towards identifying methods to diagnose this type of cancer in its early stages. Over the last decade, there has been robust research into identifying methods to detect GI cancers in their early stages with a particular emphasis on circulating biomarkers for this purpose. The present report is a review compounded from over 140 research papers on the emerging influence of circulating biomarkers in this regard. Circulating biomarker-based diagnosis via liquid biopsy offers several advantages over traditional diagnostic methods, such as colonoscopy, because the method is noninvasive; it can be used to monitor tumor load with respect to medication; and it can be used to predict recurrence. This review is largely divided into two relevant subtopics: biomarkers to diagnose gastrointestinal neuroendocrine tumors and genetic biomarkers used to diagnose common GI cancers. We focus on DNA-based biomarkers and the associated epigenetic dysregulation seen in these cancer types. Research into this area is urgently needed, and through this review chapter, the reader will gain a broad understanding of the various current uses of circulating biomarkers for both early diagnosis and prognosis of GI cancers.

Folate-targeted immunotherapies: Passive and active strategies for cancer.

The glycoprotein FRα is a membrane-attached transport protein that is shielded from the immune system in healthy cells. However, it is upregulated in various malignancies, involved in cancer development and is also immunogenic. Furthermore, FRα is a tumor-associated antigen endowed with unique properties, thus rendering it a suitable target for immunotherapeutic development in cancer. Various anti- FRα immunotherapeutic strategies are thus currently being developed and clinically assessed for the treatment of various solid tumors. These approaches include passive anti-FRα immunotherapies, such as monoclonal antibodies, or active immunotherapies, such as CART, folate haptens and vaccines. In this review, we will explore the advances in the field of FRα-based immune therapies and discuss both their successes and shortcomings in the clinical setting.

Small molecule tyrosine kinase inhibitors and pancreatic cancer-Trials and troubles.

Pancreatic cancer (PC) is an aggressive carcinoma and the fourth cause of cancer deaths in Western countries. Although surgery is the most effective therapeutic option for PC, the management of unresectable, locally advanced disease is highly challenging. Our improved understanding of pancreatic tumor biology and associated pathways has led to the development of various treatment modalities that can control the metastatic spread of PC. This review intends to present trials of small molecule tyrosine kinase inhibitors (TKIs) in PC management and the troubles encountered due to inevitable acquired resistance to TKIs.

Resistoflavine, cytotoxic compound from a marine actinomycete, Streptomyces chibaensis AUBN1/7.

In our systematic screening programme for marine actinomycetes, a bioactive Streptomycete was isolated from marine sediment samples of Bay of Bengal, India. The taxonomic studies indicated that the isolate belongs to Streptomyces chibaensis and it was designated as S. chibaensis AUBN1/7. The isolate yielded a cytotoxic compound. It was obtained by solvent extraction followed by the chromatographic purification. Based on the spectral data of the pure compound, it was identified as quinone-related antibiotic, resistoflavine (1). It showed a potent cytotoxic activity against cell lines viz. HMO2 (Gastric adenocarcinoma) and HePG2 (Hepatic carcinoma) in vitro and also exhibited weak antibacterial activities against Gram-positive and Gram-negative bacteria.

1-Hydroxy-1-norresistomycin, a new cytotoxic compound from a marine actinomycete, Streptomyces chibaensis AUBN1/7.

In our systematic screening programme for marine actinomycetes, a bioactive streptomycete was isolated from marine sediment samples of the Bay of Bengal, India. The isolate yielded a new cytotoxic compound. This was obtained by solvent extraction followed by chromatographic purification. The pure compound was identified from spectroscopic data as a quinone-related antibiotic, 1-hydroxy-1-norresistomycin (1). It showed a potent cytotoxic activity against cell lines viz. HMO2 (gastric adenocarcinoma) and HePG2 (hepatic carcinoma) in vitro. It also exhibited antibacterial activities against Gram-positive and Gram-negative bacteria.